Immunovant (IMVT) Other Operating Expenses (2019 - 2023)

Immunovant (IMVT) posted Other Operating Expenses of $12.5 million for Q2 2023, up 25.0% on a QoQ basis from $10.0 million in Q4 2022.

Immunovant (IMVT) Other Operating Expenses (2019 - 2023) Analysis & Trends

Immunovant's Other Operating Expenses history runs 3 years deep, the most recent figure standing at $12.5 million for Q2 2023.

Quarterly Other Operating Expenses changed N/A year-over-year to $12.5 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $12.5 million (up 25.0% YoY) and the FY2024 annual result came in at $12.5 million, up 25.0% from the prior year.
Other Operating Expenses was $12.5 million for Q2 2023 at Immunovant, up from $10.0 million in the prior quarter.
Across five years, Other Operating Expenses topped out at $12.5 million in Q2 2023 and bottomed at -$8.9 million in Q1 2019.
A 3-year average of $4.5 million and a median of $10.0 million in 2022 frame the typical range for Other Operating Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immunovant	7.18 Bn	7.18 Bn	-

Download Data